Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $40.00 price objective on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $33.43 on Tuesday. Monopar Therapeutics has a 12 month low of $1.72 and a 12 month high of $54.30. The stock has a fifty day moving average price of $38.52 and a 200 day moving average price of $24.54. The company has a market cap of $203.99 million, a P/E ratio of -16.97 and a beta of 1.18.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC bought a new position in Monopar Therapeutics in the 4th quarter valued at about $23,435,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $13,182,000. RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Point72 Asset Management L.P. acquired a new position in shares of Monopar Therapeutics during the fourth quarter valued at approximately $3,694,000. Finally, ADAR1 Capital Management LLC bought a new stake in Monopar Therapeutics during the fourth quarter worth approximately $2,861,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.